Genentech Phase III CELESTIMO shows Lunsumio regimen improves PFS
Genentech said its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met the primary endpoint with statistically significant, clinically meaningful PFS improvement versus Rituxan plus lenalidomide in relapsed/refractory follicular lymphoma; OS data are immature and safety showed no new signals.